Cancer biomarker testing in global clinical trials faces a persistent challenge: inconsistent interpretation among pathologists. Discovery Life Sciences and Mindpeak said on March 24, 2026, that they have formed a partnership to address this problem directly by integrating AI-powered digital image analysis into histopathology services for immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) applications.
The Core Problem: Pathologist Variability in Biomarker Interpretation
Inconsistent biomarker interpretation among pathologists contributes to variability in patient stratification. Moreover, it undermines confidence in critical go/no-go decisions during drug development. The two companies said the partnership targets this challenge by combining Mindpeak’s AI platform with Discovery’s tissue biomarker services for IHC and mIF slide analysis.
How the Partnership Works
Mindpeak’s technology functions as a risk-reduction tool for biopharmaceutical companies. Specifically, it improves interpretation consistency across pathologists through AI-assisted pathology workflows, pathologist training via Mindpeak’s peakAcademy program, and AI-guided microdissection algorithms for isolating specific tissue regions with high precision.
Discovery contributes an established clinical infrastructure to the alliance. The company’s Biomarker Academy, a peer-based pathologist training program founded in 2008, has trained more than 6,000 specialists in biomarker interpretation and scoring over the past 15 years. Furthermore, Discovery has supported more than 2,000 clinical trial programs, with 350 currently active, and has completed more than 35 IVDR-compliant studies across 16 EU countries covering 25 biomarkers over the past four years.
Cancer Biomarker Testing and AI Integration
The partnership extends Discovery’s existing artificial intelligence capabilities, which currently focus on hematoxylin and eosin (H&E) staining analysis for biospecimens. These include automated quality control, tumor burden measurement, and detailed tumor microenvironment characterization across multiple therapeutic areas.
“As AI use in pathology for clinical research purposes grows, this partnership with Mindpeak enables the integration of modeling tools that can enable improved accuracy in biomarker analysis. Combining these AI capabilities with our clinical trial expertise will help drive the development of biomarker-driven therapies.”
Greg Herrema, CEO, Discovery Life Sciences
“This collaboration with Discovery Life Sciences provides access to our AI-based platform, training, and microdissection tools, supporting researchers in IHC and mIF applications and helping achieve greater consistency and confidence in biomarker assessment.”
Felix Faber, Founder and CEO, Mindpeak
Regulatory Compliance and Data Reproducibility
The alliance aims to streamline trial operations and improve data reproducibility in regulated environments. As a result, the companies said this supports more confident decisions in patient stratification and therapy development. Both companies operate within frameworks relevant to health technology and clinical diagnostics, including EU IVDR compliance requirements.
Upcoming Presentation at AACR 2026
Additional details about the partnership and use cases will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026. Attendees can participate in a flash presentation at the Discovery Life Sciences exhibit booth from April 17 to 22 at the San Diego Convention Center in San Diego, California. Interested parties can contact the company at [email protected] for more information.